secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K/A
Filed at:   2024-08-26T23:59:59+00:00
Accession:  0001213900-24-072598
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpinCo reports $14.3M net loss for nine months; going concern uncertainty raised
--------------------------------------------------------------------------------

- Net loss of $14.3M for nine months ended June 30, 2024 (vs $7.5M prior year); no revenue.
- Working capital deficit of $21.4M; cash balance $0 at June 30, 2024.
- Due to related party (Citius Pharma) $30.9M, up from $19.5M at Sept 30, 2023.
- Company expresses substantial doubt about ability to continue as going concern within one year.
- Stock-based compensation expense $5.8M for the nine months; $40M in-process R&D asset for LYMPHIR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024072598/0001213900-24-072598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024072598/ea0212260-8ka1_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-072598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer